Low toxicity activators derived from diaminodiphenylcarbinol for the curing of acrylic bone cements.

The aim of the present invention is the development of cold- curing acrylic formulations with low toxicity activators derived from diaminodiphenylcarbinol. The proposed activators are similar to 4,4'- bis-dimethylaminobenzydrol (BZN), which is the most representative compound of the series. Lethal dose 50 in mice of BZN is 3 times superior to that of DMT. This activator provides exotherms of decreasing peak temperature with values 10ºC lower than those obtained for the commercial formulations. Mechanical porperties of the cured cements are comparable to those of commercial cements with higher values of tensile strength. The tissue response to the implantation of a cement formulated with BZN in the femur of rabbits reveales an early and more abundant osseous neoformation, starting in a period of 1-2 days and following progressively at different periods of time, with high cellular activity. INNOVATIVE ASPECTS Use of activators with antiseptic properties for the curing of acrylic bone cements COMPETITIVE ADVANTAGES -These activators possess increased hydrophobicity in comparison with DMT and therefore, a decrease in necrosis resulting from leaching of these compounds from the bone cement into the surrounding tissues and systemic circulation is expected. -These activators present values of lethal doses 50 superior to that of DMT. -These activators are less cytotoxic than DMT on polymorphonuclear leucocytes. -These activators present higher activity againts different microorganisms than DMT . -Bone cements formulated with these activators cure at lower temperatures than compositions known in the art. -The cements formulated with these activators present beneficial effects on the regeneration process of the bone when they are implanted in the dough stage in the femur of rabbits and cure "in situ". The surrounding bone at the site of implantation showed an early and more intense osseous neoformation in comparison to that observed in presence of commercial formulations. These formulations are available for demonstration.

Patent applied on 8th February 2002.

We are looking for companies of medical sector specially in surgery, traumatology and odontology interested in license agreement and financial resources for further resarch.